Gyre Therapeutics, Inc. (GYRE) Earnings History
Annual and quarterly earnings data from 2004 to 2025
Loading earnings history...
GYRE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
GYRE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 95.4% | 9.9% | 4.3% |
| 2024 | 96.3% | 15.3% | 11.4% |
| 2023 | 95.9% | -59.3% | -81.9% |
| 2022 | 95.3% | 9.0% | 2.3% |
| 2021 | -4.5% | -1141.0% | -1198.3% |
Download Data
Export GYRE earnings history in CSV or JSON format
Free sign-in required to download data
Gyre Therapeutics, Inc. (GYRE) Earnings Overview
As of May 7, 2026, Gyre Therapeutics, Inc. (GYRE) reported trailing twelve-month net income of $5M, reflecting -55.0% year-over-year growth. The company earned $0.01 per diluted share over the past four quarters, with a net profit margin of 4.3%.
Looking at the long-term picture, GYRE's historical earnings data spans multiple years. The company achieved its highest annual net income of $12M in fiscal 2024.
Gyre Therapeutics, Inc. maintains positive profitability with a gross margin of 95.4%, operating margin of 9.9%, and net margin of 4.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including HALO ($317M net income, 22.7% margin), ARDX (-$58M net income, -15.1% margin), PRAX (-$303M net income), GYRE has room to improve margins relative to the peer group. Compare GYRE vs HALO →
GYRE Earnings vs Peers
Earnings metrics vs comparable public companies
GYRE Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5M | -58.4% | $11M | $0.02 | 4.3% | 9.9% |
| 2024 | $12M | +113.0% | $16M | $0.05 | 11.4% | 15.3% |
| 2023 | -$93M | -4137.1% | -$67M | $-1.41 | -81.9% | -59.3% |
| 2022 | $2M | +102.6% | $9M | $0.03 | 2.3% | 9.0% |
| 2021 | -$88M | -58.3% | -$84M | $-2.87 | -1198.3% | -1141.0% |
| 2020 | -$56M | -0.7% | -$57M | $-2.93 | -265.1% | -273.9% |
| 2019 | -$55M | -83.6% | -$57M | $-4.41 | - | - |
| 2018 | -$30M | -39.4% | -$34M | $-2.68 | -500916.7% | -563700.0% |
| 2017 | -$22M | -27.2% | -$22M | $-6.30 | -2118.0% | -2143.6% |
| 2016 | -$17M | -14.8% | -$20M | $-21.76 | -4246.9% | -5117.3% |
See GYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GYRE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GYRE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGYRE — Frequently Asked Questions
Quick answers to the most common questions about buying GYRE stock.
Is GYRE growing earnings?
GYRE EPS fell to $0.01, with earnings declining -55.0%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $5M.
What are GYRE's profit margins?
Gyre Therapeutics, Inc. net margin is +4.3%, with operating margin at +9.9%. Below-average margins reflect competitive or cost pressures.
How consistent are GYRE's earnings?
GYRE earnings data spans 2004-2025. The declining earnings trend is -55.0% YoY. Historical data enables comparison across business cycles.